Our Mission Our Mission

Our Mission

Empowering
precision medicine
at the local level.

Learn More

A Revolution in Molecular Profiling

Our next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets from samples a fraction of the size required by competitive technologies, enabling customers to do more molecular profiling with less sample.

Learn More

2018 WIN Symposium

HTG is proud to join the WIN Consortium on WINning the War Against Cancer.  Meet us at the 10th WIN Symposium June 25 - 26 in Paris, France.

Learn More

Careers at HTG

At HTG Molecular Diagnostics, Inc., we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world. 

Featured Positions

Scientist, Development - Tucson

Pharma Business Development Director - Boston

See All Careers

News & Events

HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

TUCSON, Ariz., Jan. 23, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

Category: Press Releases
Posted on:

Keep Reading

HTG Molecular Announces Third Statement of Work for New Clinical Assay Development Program

TUCSON, Ariz., Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program under its Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN, N.V. (NYSE:QGEN). Work for the new development program will begin immediately.

Category: Press Releases
Posted on:

Keep Reading

HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance

TUCSON, Ariz., Jan. 04, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2017, and provided initial full year 2018 revenue guidance.

Preliminary 4th Quarter and Full Year 2017 Unaudited Financial Results and Revenue Guidance for 2018:

  • Total revenue for the fourth quarter of 2017 is expected to be between $6.9 and $7.2 million, an increase of 373% to 394% over the fourth quarter of 2016.

  • Total revenue for the full year 2017 is expected to be between $13.8 and $14.1 million, an increase of 169% to 175% over total revenue for the full year 2016.

  • Collaboration revenue drove fourth quarter and full year 2017 revenue. Operating expenses for the fourth quarter are expected to be slightly higher than operating expenses in the third quarter of 2017 on an absolute dollar basis. Gross margin and net loss in the fourth quarter are expected to be improved over the third quarter of 2017, primarily as a result of collaboration profit-sharing revenue expected to be recognized in the fourth quarter.

  • Cash and cash equivalents are expected to be approximately $10.0 million as of December 31, 2017.

  • HTG is providing initial revenue guidance for the year ending December 31, 2018 in the range of $20.0 to $25.0 million.

Category: Press Releases
Posted on:

Keep Reading

2018 Cancer Research UK Cambridge Institute (CRUK)

Learn how HTG is doing their part to help find “Unanswered Questions in Precision Medicine” at the 2018 CRUK Symposium. 

Cancer Research UK Cambridge Institute | Cambridge, UK | March 1 - 2, 2018

Category: Events
Posted on:

Keep Reading

2018 Molecular Pathology in Oncology

Join HTG at the Molecular Pathology in Oncology at stand 7 and learn more about our HTG EdgeSeq PATH Assay. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of markers when tissue availability is limited.

Biomedical Research Centre | The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research | London, UK | March 15, 2018

Category: Events
Topics: Molecular Profiling, PATH Assay
Posted on:

Keep Reading

2018 Nordic Precision Medicine Forum

Join us at the 2nd Annual Nordic Precision Medicine Forum and learn how we are doing our part to help the conversation on personalized healthcare

Crowne Plaza Copenhagen Towers | Copenhagen, Denmark | March 20 - 21, 2018

Category: Events
Posted on:

Keep Reading

Resources

Find product information, specifications and gene lists here. 

Brochures

Gene Lists

Product Sheets

Safety Data Sheets

Videos


Publications

Read white papers or journal publications and view other scientific content. 

White Papers

Posters

Abstracts

Webinars


Support

Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or assays. 

User Manuals RUO

User Manuals CE-IVD

Package Inserts RUO

Package Inserts CE-IVD

Training Modules RUO

Training Modules CE-IVD

Page last updated February 22, 2018

Ready to get started?

HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.

Get in Touch